Price (delayed)
$14.81
Market cap
$1.5B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.48
Enterprise value
$1.48B
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron.
There are no recent dividends present for NTLA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.